aspirin / Generic mfg. - LARVOL DELTA

Vedolizumab-Associated Acute Pancreatitis After 5 Years of Use in a Patient With Ulcerative Colitis (ACG 2025) - "We present a case of VDZ-associated acute pancreatitis (AP) in a patient with ulcerative colitis (UC) after 5 years of therapy.Case Description/ A 32-year-old woman with left-sided UC (diagnosed 7 years ago, extending to the splenic flexure) and antiphospholipid syndrome (APLS) on aspirin for thromboprophylaxis presented with 4 days of severe, stabbing epigastric pain radiating to the back. Figure: Figure 1. Magnetic Resonance Imaging (MRI) of Abdomen Showing Pancreatitis.MRI of the abdomen showing pancreatic head (A, B) and tail (C, D) on T2 weighted imaging (A, C) and restrict diffusion (B, D) consistent with acute pancreatitis."

Clinical • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Pancreatitis • Ulcerative Colitis

A Rare Case of Giant Cell Arteritis Presenting With Progressive Dysphagia and Lingual Infarction (ACG 2025) - "Temporal artery biopsy revealed bilateral transmural inflammation, consistent with GCA, though giant cells were not seen.Treatment included prednisone 60 mg daily and aspirin 81 mg daily. First-line therapy includes high-dose steroids and aspirin, but refractory cases may require advanced treatments like tocilizumab.GCA should be considered in elderly patients presenting with dysphagia and systemic symptoms, even in the absence of classic features. Prompt recognition and treatment are essential, making rare presentations valuable in improving patient care."

Clinical • Cardiovascular • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Inflammation • Otorhinolaryngology • Vasculitis

NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=30 ➔ 12 | Trial primary completion date: Nov 2026 ➔ Jun 2025

Biomarker • Enrollment change • Enrollment closed • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Case of Extramedullary Plasmacytoma Involving the Pancreas (ACG 2025) - "The patient began systemic treatment with daratumumab, lenalidomide, aspirin, acyclovir, and dexamethasone. Extramedullary plasmacytoma (EMP) of the pancreas is rare and often appears similar to pancreatic adenocarcinoma, typically causing jaundice and abdominal pain. Early and accurate diagnosis can lead to more effective treatment, reducing unnecessary surgeries and significantly improving outcomes.Figure: Pancreatic biopsy shows predominant population of atypical plasma cells that are CD138 positive: Hematoxylin and Eosin staining, magnification x 40 and x100. Figure: Immunostain CD138 Highlighting Plasma Cells, magnification x40"

Clinical • Anemia • Cardiovascular • Dyslipidemia • Endocrine Disorders • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Melanoma • Multiple Myeloma • Pancreatic Adenocarcinoma • Pancreatic Cancer • Plasmacytoma • Solid Tumor • CD38 • SDC1

Primary Budd-Chiari Syndrome: A Silent Threat (ACG 2025) - "Due to her liver anatomy, she is not a candidate for TIPS procedure, and she was scheduled for outpatient routine paracentesis and listed for liver transplant and discharged with spironolactone, furosemide, enoxaparin, aspirin, and hydroxyurea. PBCS is extremely rare, ~ 1 case per million per year, more common in women 30-40s. (C) Showing multiple collaterals from chronic hepatic vein occlusion. (D) Yellow arrow showing intrahepatic IVC narrowing and red arrow showing engorgement corresponding to the CT images."

Cardiovascular • Essential Thrombocythemia • Fibrosis • Hepatology • Immunology • Infectious Disease • Myeloproliferative Neoplasm • Portal Hypertension • Rare Diseases • Thrombocytosis • Thrombosis

ATTEND: Randomized Phase III Trial of Tislelizumab and Chemotherapy With or Without Diphenhydramine in Advanced Non-Small Cell Lung Cancer (IASLC-WCLC 2025) - "Research has demonstrated that the concurrent use of non-steroidal anti-inflammatory drugs can significantly enhance the objective response rate in patients treated with nivolumab. Additionally, the co-administration of aspirin has been shown to lower the mortality rate among patients receiving immunotherapy. Furthermore, the H1 receptor antagonist loratadine has been found to improve survival outcomes for NSCLC...Patients are randomized (1:1) to receive either tislelizumab (200 mg) plus platinum-based doublet chemotherapy (pemetrexed 500 mg/m2 for non-squamous cell carcinoma or albumin-bound paclitaxel 260 mg/m2 for squamous cell carcinoma) every 3 weeks, with or without diphenhydramine (20 mg qd IM on day 0-2)...Secondary endpoints include objective response rate, overall survival, and toxicity profile. The ATTEND trial commenced in December 2024, and enrollment is ongoing across 19 centers in China."

Clinical • Metastases • P3 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

ANDAMAN - Aspirin twice a day and Acute Coronary Syndrome (ESC-WCC 2025) - No abstract available

Late-breaking abstract • Acute Coronary Syndrome • Cardiovascular

PANTHER - P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease (ESC-WCC 2025) - No abstract available

Clinical • Late-breaking abstract • Monotherapy • Cardiovascular • Coronary Artery Disease

TARGET-FIRST: Early aspirin discontinuation after PCI in acute MI patients (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome (ESC-WCC 2025) - No abstract available

Acute Coronary Syndrome • Cardiovascular

Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients (ESC-WCC 2025) - "Conclusion The long-term benefits of a prasugrel-based dose de-escalation strategy were not evident after switching to another single antiplatelet agent. However following prasugrel, clopidogrel could be a more favorable option than aspirin as it reduced ischemic events without increasing bleeding risk."

Clinical • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis

Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens (ESC-WCC 2025) - "Introduction The latest European Guidelines for the management of acute coronary syndromes (ACS) recommends double antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor (ticagrelor or prasugrel) for the first 12 months. However, strategies involving clopidogrel showed a higher predisposition to myocardial infarction and stent thrombosis. This opens a new perspective for future research on whether aspirin should be administered systematically in ACS or if low-risk bleeding strategies, such as DAPT with clopidogrel, should be avoided."

Retrospective data • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis

Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients (LEGACY) (ESC-WCC 2025) - "Conclusions LEGACY is the first randomized controlled trial to investigate the possibility of immediately omitting aspirin in the 12 months following PCI in a broad spectrum of NSTE-ACS patients. This trial will provide novel insights on clinical outcomes, cost-effectiveness and medication adherence in a completely aspirin-free antiplatelet strategy after PCI for NSTE-ACS."

Clinical • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Aspirin versus clopidogrel beyond 1 month after acute coronary syndrome with high bleeding risk or ST-elevation myocardial infarction: pre-specified subanalyses of the STOPDAPT-3 (ESC-WCC 2025) - "Similarly, the HRs for the co-primary bleeding endpoint were not significant in both the HBR/non-HBR subgroups (HBR: 2.6 and 3.6 per 100 person-year, HR 0.73, 95%CI 0.40–1.33; non-HBR: 0.4 and 0.6 per 100 person-year, HR 0.71, 95%CI 0.23–2.24; interaction-P=0.97) and STEMI/NSTE-ACS subgroups (HR 0.96, 95%CI 0.46–2.01, and HR 0.53, 95% CI 0.24–1.17; interaction-P=0.28). ConclusionsIn patients with ACS, aspirin monotherapy after 1-month DAPT and clopidogrel monotherapy after 1-month prasugrel monotherapy were associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after PCI, regardless of bleeding risk (HBR or non-HBR) and ACS subtypes (STEMI or NSTE-ACS)."

Acute Coronary Syndrome • Cardiovascular • Ischemic stroke • Myocardial Infarction • Thrombosis

Safety and efficacy of edoxaban monotherapy vs dual antithrombotic therapy in patients with stable coronary artery disease and non-valvular atrial fibrillation: a systematic review and meta-analysis (ESC-WCC 2025) - "Luke's Medical Center - Global City INTRODUCTION In patients with ACS or post-percutaneous coronary intervention (PCI), standard treatment is dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor, for a duration of 12 months after ACS (with or without PCI) or 6 months after CCS-PCI. Death of any cause and composite of death, myocardial infarction, stent thrombosis, urgent revascularization and stroke were not significantly different between groups. DISCUSSION Among patients with non-valvular atrial fibrillation and stable coronary artery disease, edoxaban monotherapy has demonstrated a significant reduction in bleeding events with no significant increase in ischemic events as compared with combination of edoxaban and an antiplatelet."

Monotherapy • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Myocardial Infarction • Thrombosis

Efficacy and safety of potent p2y12 inhibitors versus clopidogrel in complex percutaneous coronary intervention: a systematic review and meta-analysis (ESC-WCC 2025) - "Background: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care after percutaneous coronary intervention (PCI) to reduce the risk of adverse cardiovascular events...Potent P2Y12 inhibitors such as prasugrel and ticagrelor provide more rapid, uniform and potent platelet inhibition than clopidogrel... In patients undergoing complex PCI, DAPT with potent P2Y12 inhibitors was associated with a significant reduction in all-cause mortality and cardiovascular death, without an increased risk of major bleeding."

Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis

High bleeding risk in acute coronary syndrome means high risk of adverse cardiovascular events (ESC-WCC 2025) - "Patients were treated with DAPT (aspirin and ticagrelor or clopidogrel). Conclusion(s) HBR patients present a challenge in ACS and are susceptible to adverse ischemic events. Patient-tailored, precision medicine type intervention in selecting appropriate intervention and antiplatelet regimen becomes imperative."

Adverse events • Acute Coronary Syndrome • Cardiovascular

Is spontaneous pre-hospital coronary reperfusion in STEMI safe ? (ESC-WCC 2025) - "All patients received as soon as possible and before hospital admission loading dose of aspirin, heparin and P2Y12 inhibitor...Ticagrelor was used in main patients (n=185, 86.5%) without significant differences regarding the primary outcome comparing to clopidogrel therapy (p=0.42)...Conclusion : Spontaneous reperfusion at admission is observed in about 1/5 of STEMI patients after pre-hospital loading dose of anti thrombotic therapy including P2Y12 inhibitors, and is associated with markers of decrease of infarct size. The significant increase of pre-admission cardiac arrests observed in the TIMI 3 group, has however to be further explored as it might be a concern regarding future pre-hospital reperfusion therapy strategies."

Clinical • Cardiovascular • Myocardial Infarction

Trends in P2Y12 inhibitor use after acute coronary syndromes: insights from the ProACS registry (ESC-WCC 2025) - " Patients with a diagnosis of acute coronary syndrome upon hospital admission who were enrolled in the ProACS registry between January 2011 and December 2023 were included if they underwent PCI and received DAPT with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor or prasugrel) during the index hospitalization. This study highlights evolving trends in P2Y12 inhibitor prescriptions, driven by patient demographics, clinical factors, and updated guidelines. In this Portuguese registry, clopidogrel was the most frequently prescribed second antiplatelet agent in patients who underwent PCI after ACS. However, a notable decline in clopidogrel use was observed over time, coinciding with an increase in ticagrelor prescriptions, which has since become the predominant choice."

Acute Coronary Syndrome • Cardiovascular • Hypertension • Myocardial Infarction

Tissue factor, a membrane-associated biomarker of platelet activation, predicts 5-year cardiovascular mortality in coronary artery disease patients (ESC-WCC 2025) - "Platelet-associated TF predicted AC (HR=3.03; p=0.012) and CV-mortality (HR=3.56; p=0.008) also in aspirin-only treated patients (n=239). Conclusions. Our findings highlight that platelet-associated TF is an independent predictor of AC- and CV-mortality in CAD patients on antiplatelet therapy and it enhances the thrombotic risk stratification."

Biomarker • Clinical • Cardiovascular • Coronary Artery Disease

Left atrial appendage occlusion in combination procedures - better together? (ESC-WCC 2025) - "51% of pts were discharged on dual antiplatelet therapy, 28% on NOACs, 14% on VKAs with aspirin, and 7% on aspirin alone, similar between groups... Combining LAAO with another cardiac was associated with increased intra-procedural complication rates, but only in the first years of the technique and with first generation devices. Regarding long term outcomes, cLAAO had similar safety and efficacy when compared with iLAAO. cLAAO should be performed by experienced operators in high-volume centers, in order to ensure low complication rates."

Atrial Fibrillation • Cardiovascular

Anticoagulation after embolic stroke of undetermined source - therapeutic dilemmas. (ESC-WCC 2025) - "Patients were discharged from the neurology department on aspirin, 3 were additionally obtaining clopidogrel for 14 days after stroke. Systemic empiric anticoagulation might be considered in patients with high cardiovascular risk after ESUS episode. The use of DOAC especially in patients with frequent supraventricular tachycardia episodes and high CHA2DS2-VASc score may be an option in patients with atrial cardiopathy."

Atherosclerosis • Atrial Fibrillation • Cardiovascular • Hypertension • Ischemic stroke • Thrombosis • Ventricular Tachycardia

An exploration of sex differences in pharmacotherapy following invasive angiography for coronary artery disease (ESC-WCC 2025) - "In the acute coronary syndrome (ACS) group, females were less likely to receive β-blockers (OR=0.72, p=0.002), and there was a trend to fewer P2Y12 inhibitor (OR=0.81, p=0.079), aspirin (OR=0.80, p=0.092) and ACE-I/ARB (OR=0.85, p=0.092) medications...Conclusion Women undergoing invasive angiography for obstructive CAD, including ACS populations, were less likely to receive several OMT drugs compared to males, findings occurred across age groups. Future work will be directed at understanding why differences occurred and mechanistic consequences of differences in OMT pharmacology between females and males."

Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • Myocardial Infarction

Role of urinary 11-dehydro-thromboxane B2 as a predictor of preeclampsia in pregnant high-risk women on low-dose aspirin treatment (ESC-WCC 2025) - "Residual, TX-dependent platelet activation is associated with a shorter duration of ASA effect over the 24-hour dosing interval and may predict the occurrence of PE, despite prophylaxis with low dose ASA. Studies with a larger sample size are needed to validate the role of urinary TXM as a circulating biomarker predicting suboptimal response to ASA and PE occurrence in pregnant women at high risk for PE."

Clinical • Cardiovascular • Coronary Artery Disease • CRP

Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy (ESC-WCC 2025) - " First, a clinical pharmacist and a physician independently analysed the literature on DDI for 8 AT: 5 OAC (rivaroxaban, apixaban, edoxaban, dabigatran and acenocoumarol) and 3 AA (clopidogrel, ticagrelor and prasugrel). Aspirin was excluded as it is not known for PK DDI... Antithrombotic therapies are susceptible to numerous DDI. This simple yet important tool can help cardiologists minimize significant DDI when prescribing new AT, guiding them toward safer et more effective treatment options."

Cardiovascular